57
Views
14
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Activities of matrix metalloproteinases and tissue inhibitor of metalloproteinase-2 in idiopathic hemotympanum and otitis media with effusion

, MD, , , &
Pages 144-150 | Received 28 Feb 2007, Published online: 08 Jul 2009

References

  • Ryding M, White P, Kalm O. Eustachian tube function and tympanic membrane findings after chronic secretory otitis media. Int J Pediatr Otorhinolaryngol 2004; 68: 197–204
  • Schilder AG, Zielhuis GA, Haggard MP, van den Broek P. Long-term effects of otitis media with effusion: otomicroscopic findings. Am J Otol 1995; 16: 365–72
  • Tos M, Stangerup SE, Holm-Jensen S, Sorensen CH. Spontaneous course of secretory otitis and changes of the eardrum. Arch Otolaryngol 1984; 110: 281–9
  • Lalwani AK, Jackler RK. Spontaneous hemotympanum associated with chronic middle ear effusion. Am J Otol 1991; 12: 455–8
  • Paparella MM, Lim DJ. Pathogenesis and pathology of the “idiopathic” blue ear drum. Arch Otolaryngol 1967; 85: 249–58
  • Beaumont GD. The effects of exclusion of air from pneumatized bones. J Laryngol Otol 1966; 80: 236–49
  • Mogi G. Idiopathic hemotympanum. Laryngoscope 1968; 78: 433–40
  • Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197–250
  • Antonelli PJ, Schultz GS, Kim KM, Cantwell JS, Sundin DJ, Pemberton PA, et al. Alpha 1-antitrypsin and ilomastat inhibit inflammatory proteases present in human middle ear effusions. Laryngoscope 2003; 113: 1347–51
  • Jennings CR, Guo L, Collins HM, Birchall JP. Matrix metalloproteinases 2 and 9 in otitis media with effusion. Clin Otolaryngol Allied Sci 2001; 26: 491–4
  • Schonermark M, Mester B, Kempf HG, Blaser J, Tschesche H, Lenarz T. Expression of matrix-metalloproteinases and their inhibitors in human cholesteatomas. Acta Otolaryngol (Stockh) 1996; 116: 451–6
  • Wilmoth JG, Schultz GS, Antonelli PJ. Matrix metalloproteinases in a gerbil cholesteatoma model. Otolaryngol Head Neck Surg 2003; 129: 402–7
  • Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111–22
  • Carrie S, Hutton DA, Birchall JP, Green GG, Pearson JP. Otitis media with effusion: components which contribute to the viscous properties. Acta Otolaryngol (Stockh) 1992; 112: 504–11
  • Snoek-van Beurden PA, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 2005; 38: 73–83
  • Sano S, Kamide Y, Schachern PA, Paparella MM. Micropathologic changes of pars tensa in children with otitis media with effusion. Arch Otolaryngol Head Neck Surg 1994; 120: 815–19
  • Banerjee AR, James R, Narula AA. Matrix metalloproteinase-2 and matrix metalloproteinase-9 in cholesteatoma and deep meatal skin. Clin Otolaryngol Allied Sci 1998; 23: 345–7
  • Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237–41
  • Lim DJ. Tympanic membrane. Electron microscopic observation. I: pars tensa. Acta Otolaryngol (Stockh) 1968; 66: 181–98
  • Ars BM. Tympanic membrane retraction pockets. Etiology, pathogeny, treatment. Acta Otorhinolaryngol Belg 1991; 45: 265–77
  • Shambaugh GE. The blue drum membrane. Arch Otolaryngol 1929; 10: 238–40

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.